Navigation Links
Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer

being studied as a single agent and in combination with docetaxel chemotherapy in two Phase 3 clinical trials expected to enroll approximately 1,200 patients with metastatic HRPC. Cell Genesys received Special Protocol Assessments (SPA) from the Food and Drug Administration (FDA) for each of the Phase 3 studies and has also received Fast Track designation for the product. GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently developing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties tha
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
11. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
Post Your Comments:
(Date:11/28/2014)...  (Booth #7309, North Hall) — Dicom Systems ... DCMSYS Interface WebBridge, at the 100th annual RSNA Meeting ... Chicago, Illinois . ... for medical facilities of any size, WebBridge allows any ... non-standard data (e.g. JPEG, TFF, PDF, TXT, etc.) to ...
(Date:11/27/2014)... 2014 Hovione announced today it ... with the U.S. Food and Drug Administration (FDA). This ... improved drug delivery options for established drugs. ... formulation using a new patented crystalline base form of ... prescribed oral antibiotics for acne. Currently, there are no ...
(Date:11/26/2014)... 26, 2014  Perrigo Company plc ("Perrigo") (NYSE: ... "Quality Affordable Healthcare Products®," today announced the closing of ... sale of 6,809,210 ordinary shares at a public offering ... of the option to purchase up to an additional ... Barclays Capital Inc., as representatives of the several underwriters. ...
Breaking Medicine Technology:Dicom Systems Announces WebBridge Interface at RSNA 2014 2Hovione Files its First Investigational New Drug Application With the FDA 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4
... the Potential Utility of Modigene,s CTP Technology ... ... Va., Sept. 24 Modigene Inc. (OTC,Bulletin Board: MODG) today reported ... journal Endocrinology showing that,erythropoietin (EPO) linked to Modigene,s carboxyl terminal peptide ...
... 24 Iodine has been used as an,antimicrobial ... about molecular,iodine yet many women suffering from Fibrocystic ... may soon yield an effective,nonhormonal treatment. While ... market, all,available hormonal therapies have significant adverse events. ...
Cached Medicine Technology:Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 2Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 3Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 4Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease 2
(Date:11/28/2014)... Novatus, a leading provider of ... which provides customers with greater reporting capabilities, more ... “As we continue to evolve and grow the ... and improved performance in response to requests from ... “With the enhancements that we have made to ...
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently ... Dr. Jeffrey Epstein is excited to offer patients ... platform, the site is uniquely designed for easing viewing ... 75% of all prospective rhinoplasty patients research upcoming procedures ... on with smartphones, tablets, and laptops, as well as ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... PA (PRWEB) November 28, 2014 An inventor ... curing light on a patient’s filling and it was almost ... more ergonomic curing light," she said. , The patent-pending Access ... It eases access to areas of the mouth, as well ... promotes efficiency and safety. Easy to use and clean, it ...
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2
... cancer surgeons regularly confer with plastic surgeons prior to surgery, ... a new study led by researchers at the University of ... breast cancer treatment can vary widely ranging from small ... the type of care a woman receives when it comes ...
... ,PHOENIX, Ariz. Aug. 31, 2010 The first study ... how they affect cell growth has identified two potential anti-cancer ... Genomics Research Institute (TGen) published this month in the journal ... aggressive cancer lesions that occur most frequently in the bones ...
... exposed to violence in their community are at an increased ... asthma or any cause, according to new research from the ... violence has been linked to more symptoms in pediatric asthma ... a longitudinal study showing a connection in an adult population ...
... cancer deaths worldwide, and the prognosis is generally poor, ... one type of lung cancer, adenocarcinoma, has been increasing ... in tumor cell biology that result in a more ... tissue) that have been completely surgically removed may help ...
... Portugal: Hundreds of millions of euros are being ... consulting community pharmacists rather than going straight to their ... 1 September) at the annual conference of the International ... million was freed up in one year for other ...
... Selenium effects may vary according to individual,s characteristics. ... cancer. According to results of a study published ... Prevention , a journal of the American Association for Cancer ... cancer. "The lower the levels of selenium, the ...
Cached Medicine News:Health News:Surgeons impact whether a woman gets breast reconstruction, U-M study finds 2Health News:TGen finds therapeutic targets for rare cancer in children 2Health News:Violence in inner city neighborhoods contributes to trouble with asthma 2Health News:Tumor budding identified as predictor for unfavorable outcome in lung cancer 2Health News:Health advice from pharmacists saves hundreds of millions of euros 2Health News:Health advice from pharmacists saves hundreds of millions of euros 3Health News:Increasing selenium intake may decrease bladder cancer risk 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Medicine Products: